NeuroPace Seeks $75M In IPO
The California neuromodulation company filed a registration with the US Securities and Exchange Commission to sell common stock on NASDAQ under the ticker NPCE.
You may also be interested in...
NeuroPace Raises $67M To Help Commercialize RNS System For Epilepsy
The latest financing round will also support a new clinical trial of the RNS system for children with epilepsy.
Cardio Catch-Up: Two Studies Support Boston Scientific’s Subcutaneous ICD
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition covers the two clinical studies of Boston Scientific's Emblem MRI subcutaneous implantable cardioverter defibrillator.
Cardio Catch-Up: Boston Scientific's Next-Gen Watchman FLX Pro Reduces Thrombi Risk In Trials
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. Boston Scientific is promoting pre-clinical research of the next generation version of its Watchman left-atrial appendage closure device